Page 17 - journal_14-2_Full

119

§«“¡ª«¥ à«π°“√„™â “√ °—¥®“°°—≠™“æ∫«à“ “√ „π‡´≈≈å¡–‡√Áß≈”‰ â æ∫«à“ CBD ®—∫°—∫ CB1 recep-

°—¥∑’Ë∑”‡ªìπ≈—°…≥–¬“æàπ„μâ≈‘Èπ “¡“√∂√–ß—∫ tor “¡“√∂¬—∫¬—Èß°“√‡®√‘≠‡μ‘∫‚μ¢Õ߇´≈≈å¡–‡√Áß
[23]
§«“¡ª«¥„πºŸâªÉ«¬¡–‡√Áß∑’Ë°“√„™â strong opioids ‰¥â
[18]
‰¡à‰¥âº≈ πÕ°®“°π’Ȭ—ß¡’°“√»÷°…“°“√ÕÕ°ƒ∑∏‘Ï¢Õß CBD
4. ¬“πÕπÀ≈—∫ (anxiety and sleep) ‡°’ˬ«°—∫°“√¬—∫¬—Èß°“√·æ√à°√–®“¬¢Õ߇´≈≈å¡–‡√Áß
®“°°“√»÷°…“°“√„™â cannabinoid delta-9- ‚¥¬°√–μÿâπ°“√· ¥ßÕÕ°¢Õ߬’π intra cellular
THC ¢π“¥ 15 ·≈– 20 ¡‘≈≈‘°√—¡ „πºŸâªÉ«¬∑’Ë¡’ adhesion molecule-1 (ICAM-1) „π‡´≈≈å¡–‡√Áß
[24]
Õ“°“√ª«¥ æ∫«à“ “¡“√∂™à«¬∑”„À⺟âªÉ«¬¡’Õ“°“√ ß∫ ªÕ¥
≈¥§«“¡«‘μ°°—ß«≈≈߉¥â πÕ°®“°π’È°“√»÷°…“°“√„™â °“√∑¥≈Õß„π —μ«å∑¥≈Õßæ∫«à“ THC “¡“√∂

¬“ dronabinol „πºŸâªÉ«¬‚√§¡–‡√Áß · ¥ß„Àâ‡ÀÁπ ¬—∫¬—Èß°“√‡®√‘≠‡μ‘∫‚μ¢Õß¡–‡√ÁßÀ≈“¬™π‘¥ ‡™àπ „π
[25]
«à“¬“π’ș૬„À⺟âªÉ«¬¡’Õ“°“√ºàÕπ§≈“¬·≈–À≈—∫‰¥â¥’ ¡–‡√Áߪե™π‘¥ adenocarcinoma à«π„πÀπŸ∑’Ë
¢÷Èπ æ√àÕß¿Ÿ¡‘§ÿâ¡°—πª≈Ÿ°∂à“¬‡´≈≈å¡–‡√Áߪե™π‘¥ non-

small cell lung carcinoma °Áæ∫«à“ THC “¡“√∂
¢âÕ¡Ÿ≈°—≠™“°—∫‚√§¡–‡√Áß
≈¥¢π“¥°âÕπ¡–‡√Á߉¥â 60 % „π°≈ÿà¡∑’Ë„™â THC
[26]
°“√»÷°…“æ√’§≈‘π‘° √–¥—∫‡´≈≈å·≈– —μ«å∑¥≈Õß ‡ª√’¬∫‡∑’¬∫°—∫°≈ÿࡧ«∫§ÿ¡ °“√»÷°…“ CBD ¬—ß
(Laboratory/Animal/Preclinical studies) · ¥ß‰¥â‡ÀÁπ°“√ªÑÕß°—π¡–‡√Áß (chemopreventive
cannabinoids ¡’ƒ∑∏‘Ï„π°“√¬—∫¬—È߇´≈≈å¡–‡√Áß effect) ‚¥¬ “¡“√∂¬—∫¬—Èß°“√‡°‘¥μ‘Ë߇π◊ÈÕßÕ° (Polyp)
[27]
´÷ËßÕ“®‡ªìπº≈¡“®“°À≈“¬°√–∫«π°“√ ‡™àπ °“√ ∑’ËÕ“®°≈“¬‡ªìπ¡–‡√Áß≈”‰ â„πÕπ“§μ ·≈–¬—ß¡’
[28]
°√–μÿâπ°√–∫«π°“√¶à“엫쓬·∫∫Õ–æÕæ‚∑´’ §ÿ≥ ¡∫—μ‘μâ“π°“√Õ—°‡ ∫ (anti-inflammatory)
(apoptosis) ¢Õ߇´≈≈å¡–‡√Áß °“√¬—∫¬—Èß°“√‡æ‘Ë¡ Õ¬à“߉√°Áμ“¡∫“ß°“√»÷°…“„πÀπŸæ√àÕß¿Ÿ¡‘§ÿâ¡°—π

®”π«π¢Õ߇´≈≈å (cell proliferation) À√◊ÕÕ“®‡°‘¥ °≈—∫æ∫«à“ THC °√–μÿâπ°“√‡®√‘≠‡μ‘∫‚μ·≈–°“√
[29]
®“°°“√¬—∫¬—Èß°“√‡°‘¥‡ âπ‡≈◊Õ¥„À¡à (angiogenesis) °√–®“¬μ—«¢Õ߇´≈≈å¡–‡√Áß
√«¡∂÷ß°“√·æ√à°√–®“¬¢Õ߇´≈≈å¡–‡√Áß (metastasis)
°“√»÷°…“∑“ߧ≈‘π‘°„π§π (Human/Clinical
º≈°“√»÷°…“ THC ·≈– “√ —߇§√“–Àå∑’Ë°√–μÿâπμ—«√—∫
studies)
CB2 receptor æ∫«à“ “√π’È¡’§«“¡ “¡“√∂¬—∫¬—Èß

°“√‡®√‘≠‡μ‘∫‚μ¢Õ߇´≈≈å¡–‡√Áßμ—∫„πÀ≈Õ¥∑¥≈Õß §«“¡‡ ’ˬßμàÕ°“√‡°‘¥¡–‡√Áß (Cancer risk)
[19]
·≈–„πÀπŸ∑’Ë¡’°“√ª≈Ÿ°∂à“¬‡´≈≈å¡–‡√Áßμ—∫ à«π °“√»÷°…“∑“ß√–∫“¥«‘∑¬“·∫∫ case-cohort
°“√»÷°…“„πÀ≈Õ¥∑¥≈ÕߢÕß cannabidiol (CBD) studies ∑’Ë√«¡¢âÕ¡Ÿ≈®“° 3 °“√»÷°…“„π∑«’ªÕ‡¡√‘°“

°—∫‡´≈≈å¡–‡√Á߇μâ“π¡æ∫º≈°“√«‘®—¬§≈⓬°—π«à“ CBD μ–«—πμ°‡©’¬ß‡Àπ◊Õ æ∫«à“ ºŸâ∑’Ë Ÿ∫∫ÿÀ√’Ë·≈–¡’°“√ Ÿ∫
“¡“√∂‡Àπ’ˬ«π”„À⇴≈≈å¡–‡√Á߇°‘¥ apoptosis ∑—Èß °—≠™“√à«¡¥â«¬®–¡’§«“¡‡ ’ˬßμàÕ°“√‡°‘¥‚√§¡–‡√Áß
[30]
„π‡´≈≈å™π‘¥∑’ˇªìπ estrogen receptor positive ·≈– ªÕ¥ „πª√–‡∑» À√—∞Õ‡¡√‘°“¡’°“√»÷°…“™π‘¥
[20-22]
estrogen receptor negative à«π°“√»÷°…“ retrospective cohort study ∑’Ë¡’°≈ÿà¡μ—«Õ¬à“ß